The Successful Launch and Diffusion of New Therapies - Innovation and Marketing in the Pharmaceutical Industry - page 221

Urban GL, Weinberg BD, Hauser JR (1996) Premarket forecasting of really-new products. J Mark
60:47-60
Vakratsas D, Kolsarici C (2008) A dual-market diffusion model for a new prescription pharmaceu-
tical. Int J Res Mark 25(4):282-293
Van den Bulte C (2000) New product diffusion acceleration: measurement and analysis. Mark Sci
19(4):366-380
Van Den Bulte C, Joshi YV (2007) New product diffusion with influentials and imitators. Mark Sci
26(3):400-421
Van Den Bulte C, Lilien G (1997) Bias and systematic change in the parameter estimates of macro-
Level diffusion models. Mark Sci 16(4):338-353
Van den Bulte C, Lilien GL (2001) Medical innovation revisited: social contagion versus market-
ing effort. Am J Sociol 106(5):1409-1435
Van den Bulte C, Stremersch S (2004) Social contagion and income heterogeneity in new product
diffusion: a meta-analytic test. Mark Sci 23(4):530-544
Van Everdingen YM, Fok D, Stremersch S (2009) Modeling global spill-over in new product take-
off. J Mark Res 46(5):637-652
Venkataraman S, Stremersch S (2007) The debate on influencing physicians' decisions: are drug
characteristics the missing link? Manag Sci 53(11):1688-1701
Verniers I, Stremersch S, Croux C (2011) The global entry of new pharmaceuticals: A joint inves-
tigation of launch window and price. International Journal of Research in Marketing 28(4):
295-308
Vernon JA, Golec JH, Hughen KW (2006) The economics of pharmaceutical price regulation and
importation: refocusing the debate. Am J Law Med 32(2-3):175-192
Wagner JL, McCarthy E (2004) International differences in drug prices. Annu Rev Public Health
25(1):475-495
Weerahandi S, Dalal SR (1992) A choice-based approach to the diffusion of a service: forecasting
fax penetration by market segment. Mark Sci 11(1):39-53
Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R (2004) Consumers'
reports on the health effects of direct-to-consumer drug advertising. Health Aff W3:82-95
Wilkes MS, Bell RA, Kravitz RL (2000) Direct-to-consumer prescription drug advertising: trends,
impact, and implications. Health Aff 19(2):110-128
Wittink DR (2002) Analysis of ROI for pharmaceutical promotions (ARPP). Paper presented to
the Association of Medical Publications, 18 Sept 2002. Available at http://www.vioworks.com/
clients/amp
Zachry WM, Shepherd MD, Hinich MJ, Wilson JP, Brown CM, Lawson KA (2002) Relationship
between direct-to-consumer advertising and physician diagnosing and prescribing. Am J
Health Syst Pharm 59(1):42-49